STUDresearch · Peptide
AOD-9604
Also known as
AOD 9604 · AOD9604 · Tyr-hGH177-191 · Tyr-hGH 177-191 · hGH Fragment 176-191 related marketing · lipolytic fragment peptide · Anti-Obesity Drug 9604 · hexadecapeptide 177-191 · C-terminal hGH fragment analog · sh-Oligopeptide-74 (INCI-style naming in some safety write-ups)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ / Oral
Metabolic / fat-loss peptides
Systemic fat-loss fragment claims, usually SubQ in community reports; not proven spot reduction or equivalent to oral trial dosing.
What people say
A modified growth-hormone fragment discussed for fat loss without a stimulant feeling. People look for smaller waist measurements, but oral trial results and modern SubQ stories are different evidence; spot reduction and reliable muscle sparing are not established.
Doses people talk about
Reported ranges only; the full notes retain lower 200–300 mcg charts, split-use reports, IV studies and animal joint experiments. No reconstitution or syringe calculation is implied.
How it may feel
Often described as little or no acute feeling. Waist-change accounts compete with no-change reports after weeks, frequently with GLP-1 co-use. One initially symptom-free reporter later stopped after perceived lymph-node lumps.
Community SubQ reports~250–500 mcg per day
Includes repeated 300 mcg once-daily reports; timing and splits vary, without trial-validated human SC dosing.
Upper anecdotal totals~750–1,000 mcg per day
Reported split totals in plateau discussions, not a proven escalation or safety range.
Historical oral trials0.25–30 mg daily
Separate designs: 1/5/10/20/30 mg for 12 weeks; 0.25/0.5/1 mg for 24 weeks. Not an oral-to-SubQ conversion.
Half-life & effect duration
- Half-life in the body
- IV · pigsAbout 3 minutes
- Rat-plasma breakdown testAbout 4 minutes
- Injected under the skinNo settled estimate
- Felt duration people report
- Acute feelOften little noticeable effect
- Continued use with GLP-1sWaist change at week 4 in one log; no change after 7 weeks in another
Cycles people discuss
8–12-week cut-phase runs, 12–16-week extensions and longer 12–24-week charts appear in the notes. Budget, supply and the end of a cut drive breaks; these are not validated long-term SubQ schedules.
Timing
Fasted mornings, a walk/cardio afterward and a 20–30+ minute food interval are copied rituals; some reports split AM/PM. They do not establish a fasting advantage or follow from a measured human half-life. Cloudy/gelling vials are a handling concern, not proof of activity.
Stacks
GLP-1s, CJC/ipamorelin, carnitine, stimulants and recovery blends appear alongside it. Diet, training and other compounds make any extra effect hard to isolate; the rabbit AOD/hyaluronic-acid study is not a human stack.
Access talk
No approved fat-loss drug: Historical oral obesity program ended after the late endpoint miss. 2026 buy talk is gray-market / RUO vials, not a pharmacy AOD.
Labs people mention
No AOD lab: People judge waist, photos, and the scale — not a peptide blood level.
Watch for
Source quality: Mislabeling, underfill, wrong dose, Frag↔AOD swaps, variable HPLC purity, and incomplete CoA impurity/endotoxin controls are recurring community and regulatory-risk themes.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Human SubQ half-life is not established by the reviewed evidence; the often-quoted 3 minutes is from pigs given IV AOD.
The animal paper reports rapid IV elimination and rat plasma degradation. FDA's 2024 review did not identify human PK/PD studies by any route.
Species, route, salt/formulation and parent versus metabolite measurements cannot be interchanged. This is a dated, bounded evidence search.
- Safety and metabolism of AOD9604, Moré and Kenley (2014) (opens in a new tab)Methods: pig PK; Results: Degradation pharmacokinetics/Figure 1 and Pharmacokinetic study with pigs/Figure 5.Rat plasma in vitro and pig IV/oral studies, not human SC. Figure 5 concentration units contain inconsistencies; no concentration value is promoted. Radioactivity may include degradants.
- FDA PCAC presentation: AOD-9604 (December 4, 2024) (opens in a new tab)Slide 99 (PDF p.99), Pharmacokinetics; slides 93/94 characterization; slides 102–104 oral efficacy; slides 110–113 safety and immunogenicity.FDA's 2024 search boundary, not proof that no unpublished/later human PK exists. Clinical information largely summarizes older oral/IV studies; no conversion to modern SC vials.
Felt duration people report
No dependable single-dose felt window is established; people compare waist or weight changes over weeks.
A week-4 waist-change report co-used tirzepatide; a 7-week no-change report co-used Ozempic. Little acute feeling does not identify a working or inactive product.
Uncontrolled, self-reported outcomes, no verified product or isolated AOD effect; cumulative body measurements are not a dose's felt duration.
- AOD 9604 — waist-change accounts with GLP-1 co-use (opens in a new tab)Striking-Double-9785: change in week 4 on tirzepatide maintenance and visible unanswered follow-up; FirstBlackberry6191: belly change, tirzepatide/Wolverine/Lipo-C, and own SQ daily-route clarification.Uncontrolled self-reports with diet/activity and multiple compounds. No isolated AOD attribution, measured fat distribution, one-dose duration or prevalence.
- AOD 9604: What results should I be seeing? (opens in a new tab)Glass-Serve6616 OP: 7 weeks daily AM injections added to weekly Ozempic, no change; same-author reply explains expected weight boost; Organic-Library-519 positive reply with semaglutide/diet/exercise co-use.Mixed archived thread, unverified formulations and confounded co-use. Statements that AOD is FDA-approved are commenters' misinformation, not adopted. No actual single-dose clock.
- AOD feedback — initial tolerability and later adverse account (opens in a new tab)PeachEmbarrassed1033 initial 250 mcg evening account and later own reply: perceived lymph-node lumps, stopped, resolved; JackTheif52 300 mcg daily with tirzepatide and later uncertain attribution/stall; deleted-account 2 mg vial/gelling reply.Lumps were self-described, not clinically confirmed; identity, causality and resolution interval unknown. Replies dismissing symptoms as a bad batch are not adopted. No new preparation or escalation instructions.
What people say
- Stubborn fat / waist: Modest help only when diet and training already dialed; small, confounded logs dominate; not a “dump” peptide. forum
- Muscle-sparing claim: Some cutters say they held lean mass better than deficit alone; weak attribution vs protein/training/sleep. anecdote
- Appetite: Mostly unchanged vs GLP-1s — preferred by some who want fat-path talk without nausea/satiety blunt; also explains mild results and why deficit must be self-driven. forum
- Vs Frag 176-191: Often compared, stacked, or mislabeled; cousins (AOD = Tyr-stabilized analog with formal oral obesity program), not the same molecule; community still swaps names on vials. forum
- Vs full hGH / secretagogues: Fat-path focus without growth/IGF goals or GH water look; stacks still heavily confounded by sleep, training, and water. forum
- Stack confounds: Credit often shared with carnitine, yohimbine/caffeine, cardio volume, GLP-1s, CJC/ipa, low-dose hGH, or aggressive cut drugs. forum
- Null logs: Reports of no measurable change after weeks at reported research SC amounts are a real outcome, not automatically a “bad batch.” Other threads describe waist changes, often alongside GLP-1s and other agents; neither pattern establishes an expected response for everyone. forum
- 2025–26 ‘frag that disappointed’: r/Peptides (Dec 2025 ‘is AOD doing anything?’) and r/Biohacking 2026 threads keep landing on ‘can’t tell,’ ‘waste of money,’ ‘skip it, run sema/tirz/reta.’ A Telegram-year log with ‘not one positive’ is a repeated 2025 talking point — not a trial. forum
- No strong IGF-1 rise: Core marketing draw vs full hGH — trial safety summaries report no IGF-1 elevation and no anti-AOD antibodies in assayed subjects. trial
- Glucose / insulin claim: Framed as avoiding hGH-like insulin resistance; human trials reported no meaningful glucose intolerance signal; animal work also framed as fat-path without IR penalty. trial
- Animal fat data: Chronic AOD9604 in obese mice/rats — lower weight/fat gain, higher lipolytic sensitivity / fat oxidation; β3-AR knock-out work links part of the effect. animal
- 12-wk oral signal (METAOD005 era): ~300 obese adults, oral 1 / 5 / 10 / 20 / 30 mg daily × 12 weeks; commonly cited ~2.6–2.8 kg loss at 1 mg/day vs ~0.8 kg placebo — modest, non-linear dose response (1 mg often called the best arm, not 30 mg). trial
- Later pivotal miss (METAOD006 / OPTIONS): ~500+ obese adults (secondary write-ups cite ~502–536), oral 0.25 / 0.5 / 1 mg daily × 24 weeks + diet/exercise — primary weight-loss endpoint not met at 12 or 24 weeks; development terminated. trial
- Early high-dose oral study summaries (METAOD003/004): Existing Phase IIa-style summaries describe single-dose and 7-day oral work with 9 / 27 / 54 mg capsules and increased fat-breakdown markers lasting hours after dosing. These historical summary claims are not verified human parent pharmacokinetics; FDA's 2024 review did not identify clinical human PK/PD studies. trial
- IV early clinical summaries (METAOD001/002): Single IV doses summarized around 25–400 mcg/kg (with intermediate arms such as 25 / 50 / 100 mcg/kg in one design) — historical safety/efficacy pilots, not established human PK or lifestyle SC conversion. trial
- Vs GLP-1s / dual agonists: Clinically insignificant vs sema/tirz/reta magnitude in modern framing; used as adjunct “polish,” not replacement. forum
- Vs tesamorelin: Tesamorelin has stronger visceral-fat / clinic evidence base (and approved HIV-lipodystrophy framing); AOD is fragment folklore + failed late obesity endpoint. forum
- Joint / cartilage interest: Rabbit collagenase OA model — weekly ultrasound-guided IA AOD9604 0.25 mg ± HA 6 mg for 4–7 weeks improved cartilage scores / lameness vs saline; AOD+HA beat either alone. animal
- Chondrocyte talk: In-vitro proteoglycan / type II collagen / MSC-toward-chondrocyte differentiation claims appear in secondary reviews — not human joint outcomes. lab
- Six-trial safety envelope: Secondary reviews summarize six Metabolic human studies totaling roughly ~900 participants with generally mild AE profiles — safety talk is stronger than efficacy talk. trial
- Zucker-rat oral snapshot: Often-cited rodent oral work around ~500 mcg/kg/day reduced body-weight gain substantially without the insulin-sensitivity hit associated with full GH framing. animal
Doses people talk about
- Injectable community band: ~250–500 mcg SC per day appears repeatedly in research-peptide and peptide-clinic fat-loss discussion; this is a reported band, not a validated human SC dose. forum
- Lower starter band: Some beginner stack charts and clinic-adjacent write-ups open at ~200–300 mcg SC daily. forum
- Repeated single number: ~300 mcg SC once daily, often fasted morning, appears in protocol write-ups and a reviewed account with tirzepatide; it is not an established default. forum
- Chart progression talk: An existing chart describes ~300 mcg for the first ~4 weeks, ~500 mcg in weeks 5–12 if still logging and tolerating, and optional extension at 300–500 mcg. This is an attributed chart, not a validated escalation sequence to follow. forum
- Alternate clinic-style steps: Some plans use ~300 mcg weeks 1–4 → ~400 mcg mid → ~500 mcg total (sometimes as 250 mcg BID) for longer 12–16 week blocks. forum
- Split doses: AM + pre-cardio or AM + PM (e.g. 150–250 mcg × 2, or 250 + 250) — short half-life logic, not head-to-head PD proof for SC. forum
- Upper anecdotal band: Occasional ~750–1,000 mcg/day total split if plateau; pure anecdote, not trial-backed SC. forum
- Fixed mcg, not mcg/kg: Lifestyle logs almost always use fixed microgram amounts, not weight-scaled SC charts. forum
- Fasted cardio timing: Empty-stomach AM, often ~20–30+ minutes before food/cardio, is the dominant ritual; evening-only less common except in splits. forum
- With vs without food debate: Most community protocol pages insist fasted; oral historical trials used daily capsules without the modern “fasted SC cardio” culture — different product eras. forum
- Oral research-commerce forms: Capsules/tablets still marketed in some channels; human oral bioavailability not cleanly quantified in public summaries (pig oral AUC data and rat radiography estimates exist but are not a human SC bridge). forum
- Supply-planning lore: At 300–500 mcg/day, a 5 mg vial is roughly ~10–16 days of research use before wastage; multi-month charts multiply vials accordingly — cost is a common reason people stop. forum
- Cartilage / recovery marketing doses: Secondary clinic/YouTube content sometimes lists ~250–500 mcg SC daily or EOD for “joint/cartilage” talk — not a published human IA or joint RCT protocol. forum
- Route non-equivalence: Do not convert oral trial mg ↔ SC community mcg ↔ IV mcg/kg as if bioequivalent; FDA review flagged missing published human SC PK. forum
- Purity / label risk: Labeled mcg may not equal delivered peptide; Frag vs AOD mix-ups and underfilled vials are recurring community complaints. forum
- 10 mg vial / concentration uncertainty: A 10 mg research-vial label does not establish delivered concentration, fill accuracy or a valid syringe-unit conversion; dilution assumptions cannot verify identity or sterility. A vial's nominal mass is not a preparation or syringe-draw instruction. forum
- Smaller-vial handling talk: Reports mention 2 mg and 2–5 mg vials when discussing AOD gelling, compared with 10 mg labels. Changing vial size or liquid volume does not establish a reliable concentration or validate a cloudy/gelled preparation. No syringe-draw calculation or preparation recipe is established by these reports. forum
- Oral trial mg (historical clinical): METAOD005-style arms included 1, 5, 10, 20, 30 mg/day oral × 12 weeks; OPTIONS used 0.25, 0.5, 1 mg/day oral × 24 weeks. trial
- Early oral multi-mg PD: METAOD003 single-dose and METAOD004 7-day arms used 9 / 27 / 54 mg oral capsules for safety/PD — not community vial math. trial
- Framing: Community, clinic-marketing, and historical trial ranges only — research/education context, not advice or prescriptions. forum
- IV early clinical studies: Human IV pilot safety/efficacy work is summarized around 25–400 mcg/kg, with single-dose and study-specific short-course arms. These amounts are clinical research history, not community dosing; the FDA review did not identify a published human PK/PD characterization. trial
- Topical / nasal: Marketing exists; published human exposure data sparse or absent per secondary FDA-review summaries — no supported dose conversion. trial
- Intra-articular (research only): Rabbit OA work used weekly ultrasound-guided IA 0.25 mg AOD9604 ± 6 mg HA in 0.6 mL for 4–7 weeks after collagenase induction — not a fat-loss protocol and not a published human IA dose standard. animal
How it may feel
- Days 1–7: Little subjective feel; mainly injection-site awareness if SC; non-stimulant, not GLP-1 appetite blunt or stimulant buzz. forum
- Weeks 1–2: Scale/waist noise only; appetite usually unchanged; photos and tape more useful than daily weight. forum
- Weeks 3–4: An early waist/photo check-in in existing notes, often alongside a calorie deficit. One reviewed report noticed change in week 4 on tirzepatide maintenance; a separate reporter saw no difference after 7 weeks of daily AM AOD plus weekly Ozempic. These are contrasting, confounded reports, not a predictable onset. forum
- Weeks 6–12: Early oral-trial length window; community logs still incremental, not dramatic dumps. forum
- No change by 4–6 wk: Community usually questions diet, steps, sleep, product purity — not automatic dose-doubling; some still titrate 300→500 mcg on schedule alone. forum
- Weeks 12–24: Phase IIb length; community extensions exist; controlled multi-month SC human evidence sparse. forum
- Months 2–3+ open-ended cuts: Some stay daily through longer recomp seasons while calories stay tight. forum
- Trial weekly deltas (oral era): Reported excess loss over placebo was small (on the order of ~0.06–0.15 kg/week depending on arm/write-up) — sets expectation against hype. trial
Around the dose
- Clock: Morning fasted is the fat-loss chart default. forum
- Training: Walk or fasted cardio after is the pairing people copy from HGH-frag culture. forum
- Food: Eating immediately is the thing those charts try to avoid. forum
- 2026 honesty clock: Fasted AM + walk is still copied from frag culture even when the same thread already calls AOD a dud next to GLP-1s. forum
- Gelling / cloudy vials: 2026 r/Peptides mix threads treat AOD as a pain-to-reconstitute fragment (cloudy vs gel). That is a handling complaint, not a dose chart — and it is not proof the peptide ‘worked.’ forum
Cycles people discuss
- Common community run: 8–12 weeks aligned with cut phases and early trial-length talk. forum
- Extended blocks: 12–16 weeks (and some 12–24 week clinic-style plans) mirror Phase II oral durations more than new SC science. forum
- Probe window: ~4–6 weeks to call obvious null vs keep going while diet is verified. forum
- Continuous use: Some stay daily through longer recomp seasons without a formal off; long gray-market SC safety DB is thin beyond the oral-trial window. forum
- Time off: Usually budget, supply, end of cut, or bloodwork pause — not a classical PCT. forum
- Re-runs: Often restarted next cut season; multi-year continuous unsupervised use is poorly documented. forum
- Diet coupling: Almost always assumed to ride a calorie deficit; peptide alone is not treated as a satiety drug. forum
- Missed-dose culture: Community guidance is usually skip/log and resume next scheduled pin — not double the next draw. forum
- Trial durations for context: Efficacy programs used 12 weeks (METAOD005 oral) and 24 weeks (OPTIONS / METAOD006 oral). trial
- Post-surgical / recovery marketing blocks: Some secondary content pitches ~4–6 week denser daily use for recovery framing — anecdote/marketing, not a pivotal joint RCT. forum
Timing
- Human PK boundary: The FDA's December 2024 review did not identify clinical human PK/PD studies for AOD-9604 by any route. This bounded review therefore does not establish a human SC elimination estimate; daily/BID community schedules are extrapolations, not measured SC kinetics. trialforum
- Dosing rationale in forums: Short-circulation arguments are used to explain once- or twice-daily SC talk rather than weekly-depot use. That reasoning borrows from nonclinical clocks and does not demonstrate a human SC dosing requirement. forum
- Results driver: Deficit consistency, steps, and training > chasing peak blood levels in user talk. anecdote
- Timing ritual: Fasted AM / pre-cardio dominates; evening less common except split regimens. forum
- No on-feel cue: Mild acute effects → timing is habit/protocol, not symptom-titrated. forum
- Downstream markers: No clean “AOD lab response” like IGF-1 for GH secretagogues; body comp + waist + photos carry more weight in logs. Optional IGF-1 is sometimes drawn only to document non-rise. forum
- IV half-life (pig PK): ~3 minutes after IV in pigs; near-clearance by ~12 min in an IV 400 µg/kg arm, with Tmax ~2 min. These are animal findings, not a human SC clock. animal
- In-vitro plasma degradation: Rat plasma spike work often summarized ~4 min half-life with intact peptide gone by ~56 min; cascade is mainly sequential N-terminal truncation. animal
- Degradant activity note: Principal in-vivo fragments include −2aa and −3aa species with reduced (not zero) anti-lipogenic activity in older write-ups — still not a long-depot story. animal
- Oral absorption story: Pig oral gavage shows delayed Tmax (~60 min class) with absorption then rapid degradation; rat whole-body ¹⁴C work estimated meaningful oral availability (~40% radioactivity distribution estimate) with similar organ localization to IV (pancreas, pineal, thyroid, liver, kidney cortex; CNS spared early). animal
- Human oral bioavailability: Still poorly quantified publicly despite historical oral capsule/tablet development. trial
- Detection talk (sport): WADA context includes GH-fragment prohibition; urine metabolite detection windows discussed in secondary anti-doping literature (days-scale talk in some write-ups) — athletes should treat any form as banned. trial
- vs hGH plasma life: Full hGH plasma half-life is longer (commonly ~20+ min class in PK texts); fragment is expectedly briefer — bro “active window” claims beyond clearance are mechanism speculation, not measured tissue half-life. trial
More on what it is
- Why people care: Marketed as the “fat-burning piece of GH” without IGF-1 rise, water retention, or classic GH diabetogenic sides — high search volume even after late efficacy miss. forum
- Form mismatch: Historical oral mg trials (0.25–54 mg depending on phase) ≠ modern gray-market mcg SC vial charts ≠ early IV mcg/kg pilots; routes are not interchangeable. forum
- What it is: Synthetic 16-aa peptide Tyr-hGH177-191 (sequence often written YLRIVQCRSVEGSCGF / Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) — C-terminal hGH fragment with N-terminal tyrosine for stability plus Cys–Cys disulfide cyclization; investigational anti-obesity candidate, not an approved fat-loss drug. trial
- Chemistry shorthand: Commonly listed ~C₇₈H₁₂₃N₂₃O₂₃S₂, MW ~1,815 Da; CAS numbers differ across databases (e.g. 221231-10-3 and 38624-39-7 appear in secondary sources) — identity still requires CoA, not label lore. trial
- Mechanism talk: Lipolysis up + lipogenesis down in animal/ex-vivo work; partial β3-adrenergic pathway story (effect attenuated in β3-AR knock-out mice); ligand-binding work argues it is not a high-affinity GH-receptor antagonist; FDA review notes MOA still incompletely mapped / unknown. animal
- Evidence honesty: Early oral signal and animal fat data; largest Phase IIb oral trial failed primary weight-loss endpoint; Metabolic Pharmaceuticals terminated obesity development (~Feb–Mar 2007). Talk volume > late efficacy wins. trial
- Not this: Not full hGH, not identical to Frag 176-191 (AOD adds N-terminal Tyr vs native Phe at the fragment start), not a GLP-1, not FDA-approved for weight loss or joints. trial
- Bell-curve lore: Patent/animal write-ups describe non-linear / bell-shaped dose responses in some models (higher oral mg was not always better in METAOD005) — bro “more is better” often conflicts with that history. trial
- Regulatory color: Self-affirmed GRAS-style food-ingredient framing exists in literature; WADA prohibits GH fragments including AOD-9604 (S2-class growth-hormone-fragment framing); FDA compounding Category 2 / PCAC-era significant-safety-risk discussion and later nomination-withdrawal churn exist — local clinic availability changes. trial
Stacks
- + Frag 176-191: Dual lipolytic-fragment cut stack — or pure confusion/mislabeled sibling pair; ratios not standardized; some run one or the other, not both. forum
- + L-carnitine (injectable or oral): Fatty-acid transport narrative alongside AOD on fasted cardio days; very common stubborn-fat stack culture. forum
- + Yohimbine / caffeine / stims: Classic fasted-cardio stubborn-fat stack; CV risk talk is common and separate from AOD. forum
- + GLP-1 (sema / tirz / reta): Appetite/deficit backbone + AOD as body-comp “polish”; attribution usually confounded; modern “reta + AOD” marketing stacks appear in gray-market guides. forum
- + GH secretagogues (CJC-1295 ± DAC / Ipamorelin / sermorelin / mod GRF): Parallel GH-axis + fragment fat path; sleep/recovery confounds high; sample talk often pairs AOD AM with CJC/ipa AM/PM. forum
- Sample community shape (illustrative, not a protocol): AOD ~200–500 mcg daily AM fasted + CJC/ipa ~100–200 mcg class each (study their own profiles) + deficit — multi-pin burden is real. forum
- + Low-dose hGH: Some advanced logs run fragment alongside micro-GH; sides and water from GH dominate interpretation; “belt and suspenders” fat-path lore. forum
- + Cardarine (GW501516) / other PPAR talk: Aggressive cut stacks in performance forums; multi-agent confound + separate long-term safety issues on the PPAR side. forum
- + 5-Amino-1MQ / MOTS-c / other metabolic peptides: Modern multi-peptide “metabolic” stacks; evidence for synergy is almost entirely anecdotal. forum
- Foundation still wins: Protein, progressive lifting, steps/cardio, sleep, and deficit size explain most visible change in honest logs. forum
- + Tesamorelin: Visceral-fat / GH-axis clinic framing vs AOD fragment path — sometimes compared more than co-run. forum
- + BPC-157 / TB-500 (recovery culture): Not a mechanistic fat stack; appears when users want cut + heal framing in the same season. forum
- Joint-research pairing: AOD + hyaluronic acid appears in rabbit IA literature (0.25 mg AOD + 6 mg HA weekly), not as a standard human SC fat-loss stack. animal
Access talk
- No approved fat-loss drug: Historical oral obesity program ended after the late endpoint miss. 2026 buy talk is gray-market / RUO vials, not a pharmacy AOD. trialforum
- Prescription vs gray: There is no legitimate U.S. compounded AOD path in current 2026 trackers. Clinic ads and research vials are the remaining identities. forum
- 503A nomination withdrawn: AOD-9604 is not on the 503A bulks list. FDA still publishes significant-safety-risk language (limited injectable safety info; serious AE reports of unclear causality in secondary summaries). trial
- 2024 PCAC-era no: Writeups of the Oct/Dec 2024 peptide meetings say the committee did not recommend AOD (alongside CJC-1295, ipamorelin, thymosin alpha-1 in that round). trial
- Not on the July 2026 seven: BPC/KPV/TB-500/MOTS-c/Epitalon/Semax/DSIP were the July 23–24 votes. AOD was not in that room. trial
- WADA 2026 list: Named as a growth-hormone fragment under S2.2.3 (non-Specified in 2026 list talk) — tested athletes treat any form as banned. trial
Labs people mention
- No AOD lab: People judge waist, photos, and the scale — not a peptide blood level. forum
- Optional IGF-1: Sometimes drawn only to document the ‘didn’t rise like GH’ marketing claim. forum
- Glucose lore: Trial summaries and user logs usually say no GH-like insulin-resistance hit — still not a reason to skip a baseline if someone is already drawing labs. trialforum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site / reported lumps: Redness, irritation, stinging, itch or small lumps appear in SC discussion; site rotation is a protective topic. One reporter initially described no side effects but later reported perceived lymph-node lumps and stopped; they said the lumps resolved. The cause was not established, and dismissing swelling as a bad batch is not a safety assessment. forum
- Source quality: Mislabeling, underfill, wrong dose, Frag↔AOD swaps, variable HPLC purity, and incomplete CoA impurity/endotoxin controls are recurring community and regulatory-risk themes. forum
- Drug interactions: No solid interaction charts from forums or published dedicated interaction studies; theoretical overlap with glucose/lipid/GH/beta-adrenergic agents remains speculative. forum
- Opportunity cost (2025–26): Threads compare an 8–12 week AOD run with a GLP-1 already in use or CJC/ipa. Null body-composition reports are real, not automatically bad batches; positive reports also exist and often involve stacks. These discussions do not establish a universal expected response. forum
- Headache / fatigue / dizziness: Mild events appear in trial AE lists and community logs. trial
- GI: Nausea, diarrhea, flatulence, occasional increased appetite notes in oral-trial and community talk. trial
- Other trial AE vocabulary: Nasopharyngitis, back pain, and similar non-specific events listed as mostly mild/moderate in safety summaries. trial
- Rare IV-era signal: Safety write-ups note isolated possibly related events (e.g. severe chest tightness discussed in secondary summaries of an IV arm) — not a common lifestyle SC narrative. trial
- IGF-1 / GH-class sides: Designed and reported not to raise IGF-1 or drive classic hGH edema/acromegaly pathway; still not a free pass for unsupervised long use. trial
- Immunogenicity: Anti-AOD antibodies not detected in assayed trial participants or chronic animal tox arms; FDA compounding risk write-ups still flag peptide immunogenicity/impurity/aggregate concerns for non-approved products and non-oral routes. trial
- Null result / opportunity cost: Money and injection burden for little change — consistent with failed Phase IIb obesity endpoint. trial
- No published SC human PK: Community injectable mcg charts are not the same evidence base as oral/IV trial programs; FDA review highlighted missing human SC/topical/nasal exposure data. trial
- Animal toxicology flags (non-clinical): Dose-dependent osteocalcin shifts in chronic rat oral work (direction shifted between mid and end assessments in secondary FDA summaries); periportal hepatocyte vacuolation signal in high-dose female monkeys flagged in secondary FDA-review summaries — both discussed as caution markers, not proven human clinical toxicity. animal
- Cancer listings in one oral program: Small number of cancers reported during 12-week oral METAOD005 work (various types listed in secondary reviews); investigators considered unrelated — long-term oncology safety not established. trial
- Genotox package (non-clinical): Ames / CHO chromosome aberration / micronucleus packages reported without clear genotoxic concern in sponsor-summarized safety literature. trial
- Populations without data: Pregnancy, lactation, pediatrics, active cancer history, and significant liver disease lack supportive exposure data in public trial summaries; trial populations were mainly adults with obesity. trial
- WADA / tested sport: Growth hormone fragments including AOD-9604 are prohibited; competitive athletes should treat any form as banned. trial
- Research-only framing: Not an approved medicine for fat loss or osteoarthritis; human joint outcome data is essentially absent. forum
- Compounding / regulatory: Not FDA-approved as a fat-loss drug; bulk-substance compounding has been discussed under significant-safety-risk / Category 2 style framing with later nomination-withdrawal / PCAC review churn — status and local rules change; GRAS food-ingredient claims do not equal approved obesity or joint therapy. trial
- Australia / PIED framing: Secondary sources note Australian scheduling / PIED-style control of AOD-9604 — legal status is jurisdiction-specific. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.